Home Blog of Signal Transduction Immunology & Inflammation IRAK

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

IRAK

Inhibition of IL-1 Receptor-Associated Kinase 1 Decreases Murine Acute Graft-versus-Host Disease While Preserving the Graft-versus-Lymphoma Effect

90 views | Nov 21 2023

The selective IRAK1 inhibitor Jh-X-119-01 demonstrates promise as a therapeutic intervention for acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic cell transplantation, effectively mitigating aGVHD severity while preserving the graft-versus-tumor response and hematopoietic recovery. [Read the Full Post]

Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis

288 views | Aug 19 2023

HS-276, a potent and selective orally bioavailable TAK1 inhibitor, shows promise in inhibiting TNF-mediated cytokine profiles and attenuating arthritic-like symptoms in a mouse model of inflammatory rheumatoid arthritis, suggesting it as a potential alternative to current biologic-based therapies. [Read the Full Post]

Transforming growth factor-β-activated kinase 1 (TAK1) mediates chronic pain and cytokine production in mouse models of inflammatory, neuropathic, and primary pain

236 views | Aug 19 2023

The study demonstrated that inhibiting TAK1 with the small molecule inhibitor takinib alleviated pain and inflammation in various models of chronic pain, indicating its potential as a novel drug target for the treatment of different types of chronic pain syndromes. [Read the Full Post]

Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies

180 views | Aug 09 2023

This research focused on the development of small molecule inhibitors targeting IRAK4 through molecular modeling, dynamics simulations, binding free energy calculations, and 3D-QSAR studies, leading to the design of more potent compounds for the treatment of cancer and autoimmune diseases. [Read the Full Post]

Binding Energy Partition of Promising IRAK-4 Inhibitor (Zimlovisertib) for the Treatment of COVID-19 Pneumonia

108 views | Aug 09 2023

This study utilized Fragment-Based Drug Design (FBDD) and Interacting Quantum Atoms (IQA) energy partitioning to quantitatively analyze the interactions of ligand fragments with the IRAK-4 protein target, aiding in the rational design of Zimlovisertib for the treatment of COVID-19 pneumonia. [Read the Full Post]

Rapamycin and trametinib: a rational combination for treatment of NSCLC

348 views | Jan 29 2022

Chao-Yue Sun et al. found that co-administration of rapamycin and trametinib caused a substantial suppression in tumor growth without obvious drug toxicity. Overall, our study identifies a reasonable combined strategy for treatment of NSCLC. [Read the Full Post]

Trichlorocarban induces developmental and immune toxicity to zebrafish (Danio rerio) by targeting TLR4/MyD88/NF-κB signaling pathway

890 views | Feb 04 2021

Jiaqi Xu et al. found the underlying molecular mechanisms on TCC-induced developmental and immune toxicity to zebrafish. [Read the Full Post]